Syntekabio, Teams Up with MSKCC for Next Cancer Drug

[Song Young Doo, Edaily Reporter] Syntekabio, an artificial intelligence(AI)-based drug discovery company, announced on the 16th that it will initiate an additional joint research project with the U.S.-based Memorial Sloan Kettering Cancer Center(MSKCC) to develop next-generation cancer therapeutics.

MSKCC is one of the world’s largest and most renowned cancer centers, providing a full range of cancer-related services from diagnosis and treatment to surgery, clinical trials, and cutting-edge research and education.

Following the successful completion of the first joint project launched in April to identify AI-driven anticancer drug candidates, Syntekabio has been recognized for its technological competence and will now begin co-developing a second oncology treatment with MSKCC.

The company plans to leverage its proprietary AI drug discovery platform, DeepMatcher, to rapidly and accurately identify early-stage drug candidates. Its LM-VS™ (Language Model Virtual Screening) system enables virtual screening across a chemical library of over 10 billion compounds, significantly improving hit prioritization accuracy while reducing both time and cost in the candidate discovery phase.

Jong-sun Jeong, CEO of Syntekabio, stated, “We are pleased to expand our collaboration with MSKCC and jointly develop a second oncology therapy. Continued cooperation with a world-class cancer research institution will not only accelerate small-molecule drug development but also validate the technological strength of our platform through measurable time and cost efficiencies.”

Dr. Xuejun Jiang, Director of the Cell Biology Program and the Virginia and Daniel K. Ludwig Institute at MSKCC, commented, “By leveraging AI-based platforms to explore novel mechanisms such as autophagy inhibition, we can unlock unprecedented opportunities in cancer treatment. Our partnership with Syntekabio will accelerate the transition toward faster and more targeted therapeutic strategies, paving the way for next-generation oncology therapies.”